Skip to main content
Top
Published in: Tumor Biology 10/2014

01-10-2014 | Research Article

MicroRNA-630 is a prognostic marker for patients with colorectal cancer

Authors: Dake Chu, Jianyong Zheng, Jipeng Li, Yunming Li, Jian Zhang, Qingchuan Zhao, Weizhong Wang, Gang Ji

Published in: Tumor Biology | Issue 10/2014

Login to get access

Abstract

MicroRNAs are noncoding RNAs that regulate multiple cellular processes during cancer progression. Among various microRNAs, miR-630 has recently been identified to be implicated in many critical processes in human malignancies. We investigated the expression pattern and prognostic value of miR-630 in human colorectal cancer by utilizing cancer and adjacent normal specimens from 206 patients. Quantitative real-time PCR assay was used to detect the expression of miR-630, and appropriate statistical analysis was used to evaluate the association of miR-630 with overall survival. It was found that miR-630 expression was significantly increased in colorectal cancer specimens compared with that in adjacent normal specimens. It was also proved that miR-630 expression in colorectal cancer was associated with tumor invasion, lymph node metastasis, distant metastasis, and tumor-node-metastasis (TNM) stage. The Kaplan-Meier survival analysis proved that increased miR-630 expression was associated with poor overall survival of patients with colorectal cancer. Multivariate analysis proved that miR-630 was an independent prognostic marker after adjusted for known prognostic factors. These results confirmed the overexpression of miR-630 in human colorectal cancer and its association with tumor progression. It also suggested that miR-630 expression might serve as a prognostic biomarker for patients with colorectal cancer.
Literature
1.
2.
go back to reference Center MM, Jemal A, Smith RA, Ward E. Worldwide variations in colorectal cancer. CA Cancer J Clin. 2009;59:366–78.CrossRefPubMed Center MM, Jemal A, Smith RA, Ward E. Worldwide variations in colorectal cancer. CA Cancer J Clin. 2009;59:366–78.CrossRefPubMed
3.
go back to reference Deng SX, An W, Gao J, Yin J, Cai QC, Yang M, et al. Factors influencing diagnosis of colorectal cancer: a hospital-based survey in china. J Dig Dis. 2012;13:517–24.CrossRefPubMed Deng SX, An W, Gao J, Yin J, Cai QC, Yang M, et al. Factors influencing diagnosis of colorectal cancer: a hospital-based survey in china. J Dig Dis. 2012;13:517–24.CrossRefPubMed
4.
go back to reference Chen HM, Weng YR, Jiang B, Sheng JQ, Zheng P, Yu CG, et al. Epidemiological study of colorectal adenoma and cancer in symptomatic patients in china between 1990 and 2009. J Dig Dis. 2011;12:371–8.CrossRefPubMed Chen HM, Weng YR, Jiang B, Sheng JQ, Zheng P, Yu CG, et al. Epidemiological study of colorectal adenoma and cancer in symptomatic patients in china between 1990 and 2009. J Dig Dis. 2011;12:371–8.CrossRefPubMed
5.
go back to reference Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012;62:220–41.CrossRefPubMed Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012;62:220–41.CrossRefPubMed
6.
go back to reference Wolpin BM, Meyerhardt JA, Mamon HJ, Mayer RJ. Adjuvant treatment of colorectal cancer. CA Cancer J Clin. 2007;57:168–85.CrossRefPubMed Wolpin BM, Meyerhardt JA, Mamon HJ, Mayer RJ. Adjuvant treatment of colorectal cancer. CA Cancer J Clin. 2007;57:168–85.CrossRefPubMed
8.
9.
go back to reference Kanellopoulou C, Monticelli S. A role for microRNAs in the development of the immune system and in the pathogenesis of cancer. Semin Cancer Biol. 2008;18:79–88.CrossRefPubMed Kanellopoulou C, Monticelli S. A role for microRNAs in the development of the immune system and in the pathogenesis of cancer. Semin Cancer Biol. 2008;18:79–88.CrossRefPubMed
10.
go back to reference Mayne GC, Hussey DJ, Watson DI. MicroRNAs and esophageal cancer—implications for pathogenesis and therapy. Curr Pharm Des. 2013;19:1211–26.PubMed Mayne GC, Hussey DJ, Watson DI. MicroRNAs and esophageal cancer—implications for pathogenesis and therapy. Curr Pharm Des. 2013;19:1211–26.PubMed
11.
go back to reference Mezzanzanica D, Bagnoli M, De Cecco L, Valeri B, Canevari S. Role of microRNAs in ovarian cancer pathogenesis and potential clinical implications. Int J Biochem Cell Biol. 2010;42:1262–72.CrossRefPubMed Mezzanzanica D, Bagnoli M, De Cecco L, Valeri B, Canevari S. Role of microRNAs in ovarian cancer pathogenesis and potential clinical implications. Int J Biochem Cell Biol. 2010;42:1262–72.CrossRefPubMed
12.
go back to reference Gotte M. MicroRNAs in breast cancer pathogenesis. Minerva Ginecol. 2010;62:559–71.PubMed Gotte M. MicroRNAs in breast cancer pathogenesis. Minerva Ginecol. 2010;62:559–71.PubMed
13.
go back to reference Lovat F, Valeri N, Croce CM. MicroRNAs in the pathogenesis of cancer. Semin Oncol. 2011;38:724–33.CrossRefPubMed Lovat F, Valeri N, Croce CM. MicroRNAs in the pathogenesis of cancer. Semin Oncol. 2011;38:724–33.CrossRefPubMed
14.
15.
go back to reference Dela Cruz F, Matushansky I. MicroRNAs in chromosomal translocation-associated solid tumors: Learning from sarcomas. Discov Med. 2011;12:307–17.PubMed Dela Cruz F, Matushansky I. MicroRNAs in chromosomal translocation-associated solid tumors: Learning from sarcomas. Discov Med. 2011;12:307–17.PubMed
16.
go back to reference An J, Zhu X, Wang H, Jin X. A dynamic interplay between alternative polyadenylation and microRNA regulation: IMPLICATIONS for cancer (review). Int J Oncol. 2013;43:995–1001.PubMed An J, Zhu X, Wang H, Jin X. A dynamic interplay between alternative polyadenylation and microRNA regulation: IMPLICATIONS for cancer (review). Int J Oncol. 2013;43:995–1001.PubMed
17.
go back to reference Catto JW, Alcaraz A, Bjartell AS, De Vere White R, Evans CP, Fussel S, et al. MicroRNA in prostate, bladder, and kidney cancer: a systematic review. Eur Urol. 2011;59:671–81.CrossRefPubMed Catto JW, Alcaraz A, Bjartell AS, De Vere White R, Evans CP, Fussel S, et al. MicroRNA in prostate, bladder, and kidney cancer: a systematic review. Eur Urol. 2011;59:671–81.CrossRefPubMed
18.
19.
go back to reference Okayama H, Schetter AJ, Harris CC. MicroRNAs and inflammation in the pathogenesis and progression of colon cancer. Dig Dis. 2012;30 Suppl 2:9–15.CrossRefPubMed Okayama H, Schetter AJ, Harris CC. MicroRNAs and inflammation in the pathogenesis and progression of colon cancer. Dig Dis. 2012;30 Suppl 2:9–15.CrossRefPubMed
20.
go back to reference Ma Y, Zhang P, Yang J, Liu Z, Yang Z, Qin H. Candidate microRNA biomarkers in human colorectal cancer: systematic review profiling studies and experimental validation. Int J Cancer. 2012;130:2077–87.CrossRefPubMed Ma Y, Zhang P, Yang J, Liu Z, Yang Z, Qin H. Candidate microRNA biomarkers in human colorectal cancer: systematic review profiling studies and experimental validation. Int J Cancer. 2012;130:2077–87.CrossRefPubMed
21.
go back to reference Schee K, Boye K, Abrahamsen TW, Fodstad O, Flatmark K. Clinical relevance of microRNA miR-21, miR-31, miR-92a, miR-101, miR-106a and miR-145 in colorectal cancer. BMC Cancer. 2012;12:505.PubMedCentralCrossRefPubMed Schee K, Boye K, Abrahamsen TW, Fodstad O, Flatmark K. Clinical relevance of microRNA miR-21, miR-31, miR-92a, miR-101, miR-106a and miR-145 in colorectal cancer. BMC Cancer. 2012;12:505.PubMedCentralCrossRefPubMed
22.
go back to reference Schimanski CC, Frerichs K, Rahman F, Berger M, Lang H, Galle PR, et al. High miR-196a levels promote the oncogenic phenotype of colorectal cancer cells. World J Gastroenterol WJG. 2009;15:2089–96.CrossRefPubMed Schimanski CC, Frerichs K, Rahman F, Berger M, Lang H, Galle PR, et al. High miR-196a levels promote the oncogenic phenotype of colorectal cancer cells. World J Gastroenterol WJG. 2009;15:2089–96.CrossRefPubMed
23.
go back to reference Bandres E, Cubedo E, Agirre X, Malumbres R, Zarate R, Ramirez N, et al. Identification by real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues. Mol Cancer. 2006;5:29.PubMedCentralCrossRefPubMed Bandres E, Cubedo E, Agirre X, Malumbres R, Zarate R, Ramirez N, et al. Identification by real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues. Mol Cancer. 2006;5:29.PubMedCentralCrossRefPubMed
24.
go back to reference Motoyama K, Inoue H, Takatsuno Y, Tanaka F, Mimori K, Uetake H, et al. Over- and under-expressed microRNAs in human colorectal cancer. Int J Oncol. 2009;34:1069–75.PubMed Motoyama K, Inoue H, Takatsuno Y, Tanaka F, Mimori K, Uetake H, et al. Over- and under-expressed microRNAs in human colorectal cancer. Int J Oncol. 2009;34:1069–75.PubMed
25.
go back to reference Nie J, Liu L, Zheng W, Chen L, Wu X, Xu Y, et al. MicroRNA-365, down-regulated in colon cancer, inhibits cell cycle progression and promotes apoptosis of colon cancer cells by probably targeting Cyclin D1 and Bcl-2. Carcinogenesis. 2012;33:220–5.CrossRefPubMed Nie J, Liu L, Zheng W, Chen L, Wu X, Xu Y, et al. MicroRNA-365, down-regulated in colon cancer, inhibits cell cycle progression and promotes apoptosis of colon cancer cells by probably targeting Cyclin D1 and Bcl-2. Carcinogenesis. 2012;33:220–5.CrossRefPubMed
26.
go back to reference Liu L, Chen L, Xu Y, Li R, Du X. Microrna-195 promotes apoptosis and suppresses tumorigenicity of human colorectal cancer cells. Biochem Biophys Res Commun. 2010;400:236–40.CrossRefPubMed Liu L, Chen L, Xu Y, Li R, Du X. Microrna-195 promotes apoptosis and suppresses tumorigenicity of human colorectal cancer cells. Biochem Biophys Res Commun. 2010;400:236–40.CrossRefPubMed
27.
go back to reference Galluzzi L, Morselli E, Vitale I, Kepp O, Senovilla L, Criollo A, et al. Mir-181a and miR-630 regulate cisplatin-induced cancer cell death. Cancer Res. 2010;70:1793–803.CrossRefPubMed Galluzzi L, Morselli E, Vitale I, Kepp O, Senovilla L, Criollo A, et al. Mir-181a and miR-630 regulate cisplatin-induced cancer cell death. Cancer Res. 2010;70:1793–803.CrossRefPubMed
28.
go back to reference Huang Y, Chuang A, Hao H, Talbot C, Sen T, Trink B, et al. Phospho-deltanp63alpha is a key regulator of the cisplatin-induced microRNAome in cancer cells. Cell Death Differ. 2011;18:1220–30.PubMedCentralCrossRefPubMed Huang Y, Chuang A, Hao H, Talbot C, Sen T, Trink B, et al. Phospho-deltanp63alpha is a key regulator of the cisplatin-induced microRNAome in cancer cells. Cell Death Differ. 2011;18:1220–30.PubMedCentralCrossRefPubMed
29.
go back to reference Huang Y, Guerrero-Preston R, Ratovitski EA. Phospho-deltanp63alpha-dependent regulation of autophagic signaling through transcription and micro-RNA modulation. Cell Cycle. 2012;11:1247–59.PubMedCentralCrossRefPubMed Huang Y, Guerrero-Preston R, Ratovitski EA. Phospho-deltanp63alpha-dependent regulation of autophagic signaling through transcription and micro-RNA modulation. Cell Cycle. 2012;11:1247–59.PubMedCentralCrossRefPubMed
30.
go back to reference Farhana L, Dawson MI, Murshed F, Das JK, Rishi AK, Fontana JA. Upregulation of miR-150* and miR-630 induces apoptosis in pancreatic cancer cells by targeting IGF-1R. PLoS One. 2013;8:e61015.PubMedCentralCrossRefPubMed Farhana L, Dawson MI, Murshed F, Das JK, Rishi AK, Fontana JA. Upregulation of miR-150* and miR-630 induces apoptosis in pancreatic cancer cells by targeting IGF-1R. PLoS One. 2013;8:e61015.PubMedCentralCrossRefPubMed
31.
go back to reference Wang XY, Wu MH, Liu F, Li Y, Li N, Li GY, et al. Differential miRNA expression and their target genes between NGX6-positive and negative colon cancer cells. Mol Cell Biochem. 2010;345:283–90.CrossRefPubMed Wang XY, Wu MH, Liu F, Li Y, Li N, Li GY, et al. Differential miRNA expression and their target genes between NGX6-positive and negative colon cancer cells. Mol Cell Biochem. 2010;345:283–90.CrossRefPubMed
32.
go back to reference Della Vittoria Scarpati G, Falcetta F, Carlomagno C, Ubezio P, Marchini S, De Stefano A, et al. A specific miRNA signature correlates with complete pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2012;83:1113–9.CrossRefPubMed Della Vittoria Scarpati G, Falcetta F, Carlomagno C, Ubezio P, Marchini S, De Stefano A, et al. A specific miRNA signature correlates with complete pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2012;83:1113–9.CrossRefPubMed
33.
go back to reference Corcoran C, Rani S, Breslin S, Gogarty M, Ghobrial IM, Crown J, et al. Mir-630 targets IGF1R to regulate response to her-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer. Mol Cancer. 2014;13:71.PubMedCentralCrossRefPubMed Corcoran C, Rani S, Breslin S, Gogarty M, Ghobrial IM, Crown J, et al. Mir-630 targets IGF1R to regulate response to her-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer. Mol Cancer. 2014;13:71.PubMedCentralCrossRefPubMed
Metadata
Title
MicroRNA-630 is a prognostic marker for patients with colorectal cancer
Authors
Dake Chu
Jianyong Zheng
Jipeng Li
Yunming Li
Jian Zhang
Qingchuan Zhao
Weizhong Wang
Gang Ji
Publication date
01-10-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 10/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-2223-3

Other articles of this Issue 10/2014

Tumor Biology 10/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine